We may earn commissions if you use the recommended services on this site.  

Medicenna Reports Positive Results of MDNA11 in Phase 1/2 ABILITY Study at SITC Annual Meeting

Latest Business News

Medicenna Announces Encouraging Clinical Data from MDNA11 Study

Medicenna Therapeutics Corp. has presented new clinical data from the Phase 1 monotherapy dose escalation/evaluation portion of the ABILITY-1 study. The study evaluated MDNA11, a long-acting 'beta-enhanced not-alpha' interleukin-2 (IL-2) super-agonist, in patients with advanced solid tumors. The data showed promising single-agent activity, including partial responses and durable stable disease, in patients who had progressed on multiple prior therapies. MDNA11 demonstrated a favorable safety profile and potent proliferation of effector immune populations. Medicenna believes that these findings reinforce the potential of MDNA11 as a next-generation IL-2 super-agonist for the treatment of advanced solid tumors.

Key Findings from the Study

The Phase 1 study showed a favorable safety profile, with no dose-limiting toxicities or vascular leak syndrome reported. Encouraging single-agent anti-tumor activity was observed, with partial responses in two patients and durable stable disease in three melanoma patients. MDNA11 also demonstrated potent proliferation of effector immune populations, particularly CD8+ T cells, with minimal impact on immunosuppressive Treg cells. The recommended dose for expansion in the monotherapy portion of the study was determined.

Next Steps

Medicenna plans to report results from the monotherapy expansion and combination escalation arms of the Phase 2 study in the first half of 2024. The company continues to evaluate MDNA11 as both a monotherapy and in combination with pembrolizumab (Keytruda®). In conclusion, the clinical data from the MDNA11 study highlights the promising activity and safety profile of this next-generation IL-2 super-agonist. These findings support Medicenna's ongoing efforts to develop effective immunotherapy options for patients with advanced solid tumors.

Implications of Medicenna's MDNA11 Study on New Businesses

The promising results from Medicenna's MDNA11 study could have a significant impact on new businesses in the biotech sector, particularly those focusing on cancer immunotherapies. The study's findings, which highlight MDNA11's potent anti-tumor activity and favorable safety profile, suggest that this next-generation IL-2 super-agonist could revolutionize the treatment of advanced solid tumors. For startups and new businesses, this development signals an encouraging trend in the field of oncology therapeutics. It indicates the potential for groundbreaking therapies that can deliver improved patient outcomes, even in cases where patients have progressed on multiple prior therapies.

Market Opportunities and Challenges

The success of MDNA11 could stimulate investment in similar research, presenting new market opportunities. However, it also raises the bar for innovation and safety, posing a challenge for new entrants.
Future Outlook
As Medicenna moves forward with the Phase 2 study, the biotech industry will be watching closely. The results could either pave the way for more advanced cancer treatments or serve as a learning experience for future research. Either way, the MDNA11 study is set to influence the trajectory of new businesses in this field.
Story First Published at: https://financialpost.com/globe-newswire/medicenna-announces-promising-single-agent-response-and-durability-of-mdna11-in-the-phase-1-2-ability-study-during-dose-escalation-at-the-38th-annual-meeting-of-the-society-for-immunotherapy-of-cancer
Brought to you by BusinessFormation.io
Know Your State's Registered Agent Requirements: What is a Registered Agent
Learn How To Create An LLC: What Is An LLC and How To Start an LLC Online
Business Formation Services: View Top 3 Online LLC Filing Companies

LLC Filing & Registered Agent Services

Compare Online LLC Filing Services Today

We work with the market leaders in business formation and registered agent services.

Getting started is simple and inexpensive. Form your business today & secure your brand name before someone beats you to it! Click below to view the Top 3 Best LLC and registered agent service providers.
View Top 3 Providers Now

Filing An LLC Can Be Complicated

Streamline Your LLC Filing Online for $39

Northwest Registered Agent is the best-rated service for first time filers.

Get professional LLC formation & registered agent services for only $39 + state filing fee. This offers includes your full LLC setup, plus a private business address, lifetime support, and more.

Trusted by Millions. Save 82% Today.